Mitophagy Modulation, a New Player in the Race against ALS

Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease that usually results in respiratory paralysis in an interval of 2 to 4 years. ALS shows a multifactorial pathogenesis with an unknown etiology, and currently lacks an effective treatment. The vast majority of patients exhibit...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 22; no. 2; p. 740
Main Authors Madruga, Enrique, Maestro, Inés, Martínez, Ana
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 13.01.2021
MDPI
Subjects
Adenosine triphosphate
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - drug therapy
Amyotrophic Lateral Sclerosis - etiology
Amyotrophic Lateral Sclerosis - metabolism
Animals
Autophagy
Autophagy - drug effects
Autophagy - genetics
Autophagy - immunology
Biosynthesis
Disease
Disease Management
Disease Models, Animal
Disease Susceptibility
Drug development
drug target
Etiology
Health care
Homeostasis
Humans
Metabolism
Mitochondria
Mitochondria - drug effects
Mitochondria - genetics
Mitochondria - immunology
Mitochondria - metabolism
Mitochondrial DNA
mitophagy
Mitophagy - drug effects
Mitophagy - genetics
Mitophagy - immunology
Molecular Targeted Therapy - methods
Motor neurons
Mutation
Neuromodulation
Paralysis
Pathology
Phagocytosis
Physiology
Protein interaction
Proteins
Review
Spinal cord
mitophagy
amyotrophic lateral sclerosis
mitochondria
drug target
Online AccessGet full text

Cover

More Information
Summary:Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease that usually results in respiratory paralysis in an interval of 2 to 4 years. ALS shows a multifactorial pathogenesis with an unknown etiology, and currently lacks an effective treatment. The vast majority of patients exhibit protein aggregation and a dysfunctional mitochondrial accumulation in their motoneurons. As a result, autophagy and mitophagy modulators may be interesting drug candidates that mitigate key pathological hallmarks of the disease. This work reviews the most relevant evidence that correlate mitophagy defects and ALS, and discusses the possibility of considering mitophagy as an interesting target in the search for an effective treatment for ALS.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22020740